Back to top

Tale of the Tape

Zacks Equity Research

DENTSPLY (XRAY) Q3 Earnings Top Estimates, Sales Up Y/Y
November 04, 2016

XRAY

Trades from $3

DENTSPLY SIRONA Inc (XRAY - Free Report) is one of the leading worldwide manufacturers’ dental consumables, dental laboratory products, dental specialty products and consumable medical device products.
Post DENTSPLY-SIRONA merger, the business has been organized into two reporting segments: Dental & Healthcare Consumables and Technologies.

Currently, this York, PA- based company carries a Zacks Rank #4 (Sell) but that could change following its third quarter 2016 earnings report which has just released. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. We have highlighted some of the key details from the just-released announcement below:
 

DENTSPLY SIRONA Price and EPS Surprise

 

DENTSPLY SIRONA Price and EPS Surprise | DENTSPLY SIRONA Quote

Earnings: DENTSPLY reported adjusted earnings of 66 cents per share, which beat the Zacks Consensus Estimate by 3 cents and was flat on a year-over-year basis.
 
Revenues: DENTSPLY’s net sales increased to $954.2 million from $648.9 million in the year-ago period. However this came below the Zacks Consensus Estimate of $960.0 million. Sales (excluding precious metals) of the combined businesses grew 49.2% at constant currency (cc) exchange rates.

Key Stats: Dental and Healthcare Consumables were flat year over year at cc, while Technologies grew 0.9% in the quarter.

Major Factors: The quarterly upside was driven by robust performance in the Rest of World segment. Sales of the combined businesses grew 0.4% on a constant currency basis. Sales of the combined businesses in the U.S. fell 3.1% on a constant currency basis.

During the quarter, the company repurchased an additional $100 million of shares and paid $18 million in dividends. The company raised the bottom end of its previous EPS guidance range and now anticipates adjusted EPS for 2016 in the range of $2.75 to $2.80.

Check back later for our full write up on this DENTSPLY earnings report later!

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>

In-Depth Zacks Research for the Tickers Above

DENTSPLY SIRONA (XRAY) - FREE report >>